IIT Madras & Australian Researchers Develop Precision Nanoinjection Platform for Breast Cancer Drug Delivery

Researchers from the Indian Institute of Technology Madras (IIT Madras), in collaboration with Monash University and Deakin University from Australia, have developed an innovative nanoinjection drug delivery platform aimed at enhancing the safety and effectiveness of breast cancer treatment. This groundbreaking approach combines nanoarchaeosome-based drug encapsulation with silicon nanotube (SiNT)-based intracellular delivery to create a precise and sustained therapeutic system.

The Challenge of Breast Cancer Treatment

Breast cancer remains one of the leading causes of mortality among women globally. Traditional treatment methods, such as chemotherapy and radiation, often result in damage to non-cancerous tissues due to systemic drug exposure. This limitation has necessitated the development of more targeted and effective treatment options.

Innovative Nanoinjection System

The research team from IIT Madras and their Australian counterparts devised a novel nanoinjection system that delivers the anticancer drug doxorubicin directly into cancer cells. This system utilizes thermally stable nanoarchaeosomes (NAs) loaded into vertically aligned silicon nanotubes etched onto a silicon wafer. The integration of these components enhances the therapeutic efficacy of the drug while ensuring excellent biocompatibility.

Key Features of the Nanoinjection Platform

• High Precision: The platform allows for targeted delivery of the drug, minimizing damage to healthy cells.
• Thermal Stability: The nanoarchaeosomes provide a stable environment for drug encapsulation.
• Long-term Drug Release: The system can release the drug over an extended period, up to 700 hours.
• Biocompatibility: The silicon nanotube-based design is inherently non-toxic, reducing the need for additional surface modifications.

Experimental Results

Experimental studies demonstrated that the Nanoarchaeosome-Doxorubicin–Silicon Nanotubes (NAD-SiNTs) induced significant cytotoxicity against MCF-7 breast cancer cells while sparing healthy fibroblasts. The results indicated that the NAD-SiNTs triggered cell-cycle arrest and necrosis in cancer cells. Furthermore, the platform significantly reduced angiogenesis, the process through which tumors develop new blood vessels, by downregulating key pro-angiogenic factors.

Potency and Cost-Effectiveness

The findings revealed that the platform exhibited a 23 times lower inhibitory concentration (IC50) compared to free doxorubicin, suggesting a higher potency at much lower doses. This characteristic can directly translate into lower treatment costs and fewer side effects for patients.

Advantages Over Existing Systems

The highlight of this research is its ability to address common drawbacks associated with existing nanocarrier systems, such as burst release and poor compatibility. Unlike other nanoinjection platforms made from carbon or titanium nanotubes, the silicon nanotube-based design is more reliable and scalable for future clinical applications.

Significance for Healthcare Delivery

Dr. Swathi Sudhakar, Assistant Professor and Faculty Advisor for Clinical Engineering at IIT Madras, emphasized the transformative implications of this research for healthcare delivery, particularly in low- and middle-income countries like India. She stated, “This research could have transformative implications for healthcare delivery in low- and middle-income countries like India, where access to advanced cancer therapies remains limited by cost. By enabling targeted delivery of smaller doses with higher efficacy, the system can potentially lower the overall expense of cancer treatment and improve patients’ quality of life.”

Publication and Future Directions

The research findings were published in the peer-reviewed journal Advanced Materials Interfaces, which focuses on the design, development, and application of functional materials and surfaces for advanced technologies. The paper was co-authored by several researchers, including Kaviya Vijayalakshmi Babunagappan, Subastri Ariraman, Jann Harberts, Vimalraj Selvaraj, Mukilarasi Bedatham, Narendran Sekar, Nicolas H Voelcker, Roey Elnathan, and Swathi Sudhakar.

Conclusion

The development of this precision nanoinjection platform represents a significant advancement in breast cancer treatment. By combining high precision, thermal stability, and long-term drug release, this innovative system has the potential to revolutionize cancer therapies, making them more accessible and effective for patients worldwide.

Note: The implications of this research extend beyond just breast cancer treatment, potentially influencing other areas of medicine where targeted drug delivery is crucial.